Archive

Issue of Options

The Company confirms that it has agreed to issue share options to its directors, as follows: 1. 879,521 share options over ordinary shares in…

Director Dealing

The Company announces that it received notice today that Dr Jim Millen, the Company’s CEO, has purchased a total of 200,000 ordinary shares in the…

Result of AGM

The Company is pleased to announce that all resolutions put to shareholders at the Annual General Meeting held today were passed. Please click here for…

Payment for in-silico modelling of checkpoint inhibitor

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is now entitled to a payment from Sareum…

Dispatch of Annual Report and Shareholder Circular Proposed Share Consolidation

Dispatch of Documentation: Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has published and posted…

Provisional Award of Innovate UK Grant

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been notified of Innovate UK’s intention to…

Final Results for the year ended 30 June 2016

Chairman’s Statement Summary of Results in the year ended 30 June 2016 • The turnover of the Company increased 26% to £297,120 (2015:…

Poster presentation at ACoP7 Meeting 2017

Physiomics to give an oral presentation on developments of the Virtual Tumour platform in drug resistance at the Seventh American Conference on Pharmacometrics (“ACoP7”)…

Advisor Changes

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce the appointment of Hybridan LLP as sole broker with effect…

Placing and Update on Acquisition

The Company announces that it has completed a placing, conditional only on Admission, to raise £555,000.00 from the issue of 2,220,000,000 new ordinary shares of…